Quantum Biopharma (NASDAQ:QNTM) Posts Earnings Results, Misses Expectations By $2.09 EPS

Quantum Biopharma (NASDAQ:QNTM) posted its quarterly earnings results on Friday. The company reported ($2.89) EPS for the quarter, missing the consensus estimate of ($0.80) by ($2.09), Zacks reports.

Quantum Biopharma Price Performance

Shares of NASDAQ:QNTM traded up $2.69 during midday trading on Friday, reaching $11.07. 8,900,068 shares of the company’s stock were exchanged, compared to its average volume of 1,189,524. The stock has a market cap of $21.25 million, a price-to-earnings ratio of -0.75 and a beta of 0.37. Quantum Biopharma has a fifty-two week low of $2.70 and a fifty-two week high of $18.00. The firm’s 50 day simple moving average is $6.09 and its two-hundred day simple moving average is $5.01.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.